RU98103895A - Extended activity IPRATROPY BROMIDE ENANTIOMER - Google Patents

Extended activity IPRATROPY BROMIDE ENANTIOMER

Info

Publication number
RU98103895A
RU98103895A RU98103895/04A RU98103895A RU98103895A RU 98103895 A RU98103895 A RU 98103895A RU 98103895/04 A RU98103895/04 A RU 98103895/04A RU 98103895 A RU98103895 A RU 98103895A RU 98103895 A RU98103895 A RU 98103895A
Authority
RU
Russia
Prior art keywords
inhalation
drugs
butylamino
hydroxy
ethanol
Prior art date
Application number
RU98103895/04A
Other languages
Russian (ru)
Other versions
RU2171258C2 (en
Inventor
Банхольцер Рольф
Райхль Рихард
Диссе Бернд
Шпек Георг
Original Assignee
Берингер Ингельхайм КГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19528145A external-priority patent/DE19528145A1/en
Application filed by Берингер Ингельхайм КГ filed Critical Берингер Ингельхайм КГ
Publication of RU98103895A publication Critical patent/RU98103895A/en
Application granted granted Critical
Publication of RU2171258C2 publication Critical patent/RU2171258C2/en

Links

Claims (8)

1. Соли (эндо, син)-(-)-3-(3-окси-1-оксо-2-фенилпропокси)-8-метил-8-(1-метил-этил)-8-азониабицикло[3.2.1] октана с чистотой энантиомера 90 - 100%, предпочтительно 95 - 100%.1. Salts (endo, syn) - (-) - 3- (3-hydroxy-1-oxo-2-phenylpropoxy) -8-methyl-8- (1-methyl-ethyl) -8-azoniabicyclo [3.2.1 ] octane with a purity of the enantiomer of 90-100%, preferably 95-100%. 2. Соли по п. 1, содержащие в качестве аниона Вr-, Сl- или СН3СО3 -.2. Salts according to claim 1, containing as the anion Br -., Cl - or CH 3 SO 3 -. 3. Ингаляционный препарат, отличающийся тем, что он содержит соединение по п. 1 или 2 и, при необходимости, обычные побочные вещества и/или носители и/или другие лекарственные вещества. 3. Inhalation preparation, characterized in that it contains a compound according to claim 1 or 2 and, if necessary, the usual side substances and / or carriers and / or other medicinal substances. 4. Ингаляционный препарат по п. 3, отличающийся тем, что наряду с соединением по п. 1 или 2 он содержит эффективную дозу β2-миметического средства, ингаляционно применимого стероида или ингаляционно применимого противоаллергического средства.4. The inhalation preparation according to claim 3, characterized in that, in addition to the compound according to claim 1 or 2, it contains an effective dose of a β 2 mimetic agent, an inhalation-based steroid or an inhalation-based anti-allergic agent. 5. Ингаляционный препарат по п. 4, отличающийся тем, что в качестве β2-миметического средства используют бамбутерол, битолтерол, карбутерол, кленбутерол, фенотерол, формотерол, гексопреналин, ибутерол, пирбутерол, прокатерол, репротерол, зальбутамол, зальметерол, зульфонтерол, тербуталин, тулобутерол, 1-(2-фтор-4-оксифенил)-2-[4-(1-бензимидазолил)-2-метил-2-бутиламино] этанол, эритро-5'-окси-8'-(1-окси-2-изопропиламинобутил)-2Н-1,4-бензоксазин-3-(4Н)-он, 1-(4-амино-3-хлор-5-трифторметилфенил)-2-трет. -бутиламино)-этанол, 1-(4-этоксикарбониламино-3-циан-5-фторфенил)-2-(трет.-бутиламино)-этанол, в качестве стероида - будезонид, беклометазон (или 17,21-дипропионат), дексаметазон-21-изоникотинат, флунизолид, а в качестве противоаллергического средства - динатрийкромогликат, недокромил или эпинастин.5. The inhalation preparation according to claim 4, characterized in that bambuterol, bitolterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, pirbuterol, carterol, reproterol, zalbutamol, zalterterol, zalterterol are used as a β 2 mimetic agent , tulobuterol, 1- (2-fluoro-4-hydroxyphenyl) -2- [4- (1-benzimidazolyl) -2-methyl-2-butylamino] ethanol, erythro-5'-hydroxy-8 '- (1-hydroxy -2-isopropylaminobutyl) -2H-1,4-benzoxazin-3- (4H) -one, 1- (4-amino-3-chloro-5-trifluoromethylphenyl) -2-tert. -butylamino) ethanol, 1- (4-ethoxycarbonylamino-3-cyan-5-fluorophenyl) -2- (tert.-butylamino) ethanol, as a steroid - budesonide, beclomethasone (or 17,21-dipropionate), dexamethasone -21-isonicotinate, flunisolid, and disodium cromoglycate, nedocromil or epinastine as an antiallergic agent. 6. Применение соединений по п. 1 или 2, при необходимости, в комбинации с другими лекарственными веществами, применимыми при ингаляционном лечении дыхательных путей, при получении препаратов для лечения заболеваний дыхательных путей. 6. The use of compounds according to claim 1 or 2, if necessary, in combination with other medicinal substances applicable in the inhalation treatment of the respiratory tract, upon receipt of drugs for the treatment of diseases of the respiratory tract. 7. Применение по п. 6, причем в качестве комбинационных веществ используют β2-миметические средства, стероиды или противоаллергические средства.7. The use according to claim 6, wherein β 2 mimetic agents, steroids or antiallergic agents are used as combination substances. 8. Ингаляционное применение эффективных доз лекарственных веществ по п. 1 или 2 или комбинаций этих лекарственных веществ с другими лекарственными веществами для лечения заболеваний дыхательных путей. 8. Inhalation of effective doses of drugs according to claim 1 or 2, or combinations of these drugs with other drugs for the treatment of respiratory diseases.
RU98103895/04A 1995-08-01 1996-07-31 L-(-)-enantiomer bromide of (endo,syn)-(-)-3-(3-hydroxy-1- oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azonia- bicyclo-[3,2,1]-octane with purity 90-100% and inhalation preparation for inhibition of bronchial spasm induced by acetylcholine RU2171258C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19528145.4 1995-08-01
DE19528145A DE19528145A1 (en) 1995-08-01 1995-08-01 New drugs and their use

Publications (2)

Publication Number Publication Date
RU98103895A true RU98103895A (en) 2000-01-10
RU2171258C2 RU2171258C2 (en) 2001-07-27

Family

ID=7768353

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98103895/04A RU2171258C2 (en) 1995-08-01 1996-07-31 L-(-)-enantiomer bromide of (endo,syn)-(-)-3-(3-hydroxy-1- oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azonia- bicyclo-[3,2,1]-octane with purity 90-100% and inhalation preparation for inhibition of bronchial spasm induced by acetylcholine

Country Status (37)

Country Link
US (1) US6299861B1 (en)
EP (1) EP0843676B1 (en)
JP (1) JPH11510150A (en)
KR (1) KR100445016B1 (en)
CN (1) CN1120841C (en)
AR (1) AR004179A1 (en)
AT (1) ATE208390T1 (en)
AU (1) AU6739796A (en)
BG (1) BG63780B1 (en)
BR (1) BR9609951A (en)
CA (1) CA2226934C (en)
CO (1) CO4750836A1 (en)
CZ (1) CZ291998B6 (en)
DE (2) DE19528145A1 (en)
DK (1) DK0843676T3 (en)
EE (1) EE04614B1 (en)
ES (1) ES2167592T3 (en)
HK (2) HK1013597A1 (en)
HR (1) HRP960365B1 (en)
HU (1) HU228056B1 (en)
IL (1) IL118986A (en)
MX (1) MX9800864A (en)
MY (1) MY115201A (en)
NO (1) NO317561B1 (en)
NZ (1) NZ315645A (en)
PL (1) PL183789B1 (en)
PT (1) PT843676E (en)
RO (1) RO120260B1 (en)
RU (1) RU2171258C2 (en)
SI (1) SI0843676T1 (en)
SK (1) SK283260B6 (en)
TR (1) TR199800121T1 (en)
TW (1) TW449597B (en)
UA (1) UA55391C2 (en)
WO (1) WO1997005136A1 (en)
YU (1) YU49479B (en)
ZA (1) ZA966494B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20020151541A1 (en) * 2000-10-31 2002-10-17 Michel Pairet Pharmaceutical compositions containing tiotropium salts and antihistamines and their use
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6455028B1 (en) * 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
WO2002085296A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2003221335A (en) 2001-10-26 2003-08-05 Dey Lp Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptom of chronic obstructive pulmonary disease
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20050043343A1 (en) * 2003-07-28 2005-02-24 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
ES2257152B1 (en) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
PE20060826A1 (en) * 2004-12-06 2006-10-08 Smithkline Beecham Corp OLEOPHINIC DERIVATIVE OF 8-AZONIABICICLO [3.2.1] OCTANE AND THE PHARMACEUTICAL COMBINATION THAT INCLUDES IT
WO2006114379A1 (en) * 2005-04-23 2006-11-02 Boehringer Ingelheim International Gmbh Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
TW201311649A (en) * 2011-09-05 2013-03-16 Everlight Chem Ind Corp Compounds for electrolyte of solar cell and methods of preparation thereof, electrolyte and solar cell having the same
CN111751454B (en) * 2019-03-29 2023-12-08 天津药业研究院股份有限公司 Method for detecting content of ipratropium bromide intermediate I and related substances
CN110361494B (en) * 2019-06-26 2023-08-15 四川普锐特药业有限公司 Method for detecting impurity G in ipratropium bromide aerosol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505337A (en) * 1967-12-22 1970-04-07 Boehringer Sohn Ingelheim N - hydrocarbyl-substituted noratropinium,haloalkylates and o-acyl derivatives thereof
DE2903957A1 (en) * 1979-02-02 1980-08-07 Boehringer Sohn Ingelheim AGENT FOR TREATING NASAL HYPERSECRETION
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4140861C2 (en) * 1991-12-11 2003-12-11 Boehringer Ingelheim Kg Process for the production of quaternary tropic acid alkaloids
DK0673240T3 (en) * 1992-12-09 1999-10-11 Boehringer Ingelheim Pharma Stabilized medical aerosol solution formulations

Similar Documents

Publication Publication Date Title
RU98103895A (en) Extended activity IPRATROPY BROMIDE ENANTIOMER
CA2226934C (en) Ipratropium bromide enantiomer with a prolonged duration of action
CA2075060C (en) Novel vehicle gases and their use in medical preparations
AU2002218220B2 (en) Method for producing powdery formulations
CA2368583C (en) New medicament compositions based on anticholinergically-effective compounds and .beta.-mimetics
IL97028A (en) Propellant gas mixtures and pharmaceutical compositions containing them
BR9609307B1 (en) pharmaceutical preparation for the production of lung-propellant-free inhaled aerosols as well as aerosol comprising the same.
ES2296976T3 (en) RECREATION PROCEDURE FOR THE MANUFACTURE OF POWDER FORMULATIONS.
ES2338563T3 (en) NEW CRYSTAL ANHYDRATE WITH ANTICOLINERGIC EFFECT.
RU2005107475A (en) INHALATION MEDICINES CONTAINING A NEW ANTICHOLINERGIC MEDICINE IN COMBINATION WITH CORTICOSTEROIDS AND BETAMETHYMETICS
ES2284025T3 (en) MEDICATIONS TO INHALATE THAT INCLUDE BETAMIMETICS AND AN ANTI-POLINERGIC.
RU2422144C2 (en) Application of tiotropium salts for treatment of severe forms of persistent asthma
ES2362365T3 (en) MEDICINES FOR THE PREVENTION OR TREATMENT OF CARDIAC INSUFFICIENCY THAT UNDERSTANDS THE ADMINISTRATION OF AN ANTI-POLYNERGIC.
ES2362306T3 (en) USE OF TIOTROPE SALTS IN THE TREATMENT OF PERSISTENT MODERATE ASTHMA.
AU4381800A (en) Ipratropium bromide enantiomer with a prolonged duration of action